Endoscopy 2011; 43(4): 296-299
DOI: 10.1055/s-0030-1256125
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Long-term randomized controlled trial of a novel nanopowder hemostatic agent (TC-325) for control of severe arterial upper gastrointestinal bleeding in a porcine model

S.  A.  Giday1 , 2 , Y.  Kim1 , 3 , D.  M.  Krishnamurty1 , R.  Ducharme4 , D.  B.  Liang1 , E.  J.  Shin1 , X.  Dray1 , 5 , D.  Hutcheon1 , K.  Moskowitz4 , G.  Donatelli1 , D.  Rueben6 , M.  I.  Canto1 , P.  I.  Okolo1 , A.  N.  Kalloo1
  • 1Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, USA
  • 2Department of Medicine, Division of Gastroenterology, Howard University College of Medicine, Washington DC, USA
  • 3Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
  • 4Cook Endoscopy, Winston-Salem, North Carolina, USA
  • 5Department of Digestive Diseases, Lariboisière Hospital APHP and René Diderot-Paris 7 University, Paris, France
  • 6Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, USA
Further Information

Publication History

submitted 21 August 2010

accepted after revision 3 November 2010

Publication Date:
07 March 2011 (online)

Preview

Background and study aim: Endoscopic therapy of brisk upper gastrointestinal bleeding remains challenging. A proprietary nanopowder (TC-325) has been proven to be effective in high pressure bleeding from external wounds. The efficacy and safety of TC-325 were assessed in a survival gastrointestinal bleeding animal model.

Method: 10 animals were randomized to treatment or sham. All animals received intravenous antibiotics, H2-blockers and heparin (activated clotting time 2 × normal). In a sterile laparotomy the gastroepiploic vessels were dissected, inserted through a 1-cm gastrotomy, and freely exposed in the gastric lumen, and the exposed vessel lacerated by needle knife. The treatment group received TC-325 by a modified delivery catheter while the sham group received no endoscopic treatment. Time to hemostasis, and mortality at 60 minutes, 24 hours, 48 hours, and 7 days were noted. Necropsy was performed in all animals.

Results: Spurting arterial bleeding was achieved in all animals. No control animal showed hemostasis within the first hour compared with 100 % (5 / 5) in the treatment arm (mean 13.8 minutes, P < 0.0079). Durable hemostasis was achieved with no evidence of rebleeding after 1 and 24 hours in 80 % (4 / 5) of the treated animals compared with none in the control group (P < 0.0098). None of the control animals survived more than 6 hours. Necropsy at 1 week in treated animals revealed healed gastrotomy without foreign body granuloma or embolization to the lung or brain.

Conclusion: TC-325 is safe and highly effective in achieving hemostasis in an anticoagulated severe arterial gastrointestinal bleeding animal model.

References

S. A. GidayMD 

Johns Hopkins Hospital
Division of Gastroenterology

1830 East Monument Street, Room 424
Baltimore, MD 21205
USA

Fax: +1-410-614-2490

Email: sgiday1@jhmi.edu